Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: An in vitro flow chamber model

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Hosokawa, Kazuya ^a,b   Ohnishi, Tomoko ^a   Sameshima, Hisayo ^a   Miura, Naoki ^c   Koide, Takehiko ^b   Maruyama, Ikuro ^b   Tanaka, Kenichi A ^d  

^a Fujimori Kogyo CO   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARC 66096; COLLAGEN TYPE 1; DABIGATRAN; PURINERGIC RECEPTOR BLOCKING AGENT; RIVAROXABAN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD VOLUME; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FLOW CHAMBER ANALYSIS; HUMAN; IN VITRO STUDY; MALE; MICROCHIP ANALYSIS; NORMAL HUMAN; SHEAR RATE; THROMBIN TIME; THROMBOCYTE FUNCTION;

ADENOSINE TRIPHOSPHATE; ADULT; ANTICOAGULANTS; ANTITHROMBINS; ASPIRIN; BENZIMIDAZOLES; BETA-ALANINE; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; FIBRIN; HUMANS; LAB-ON-A-CHIP DEVICES; MALE; MICROSCOPY, CONFOCAL; MORPHOLINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; THIOPHENES; THROMBIN; THROMBOPLASTIN; THROMBOSIS;

EID: 84900342168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086491     Document Type: Article

References (28)

1. Gross PL, Weitz JI (2008) New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 28: 380-386.
2. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386-399. (Pubitemid 351185753)
3. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78: 412-421. (Pubitemid 41393676)
4. Rubboli A, Di Pasquale G (2007) Triple therapy of warfarin, aspirin and a thienopyridine for patients treated with vitamin K antagonists undergoing coronary stenting. A review of the evidence. Intern Emerg Med 2: 177-181.
5. Gurbel PA, Tantry US (2010) Combination antithrombotic therapies. Circulation 121: 569-583.
6. Becker EM, Perzborn E, Klipp A, Lucker C, Butehorn U, et al. (2012) Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. J Thromb Haemost 10: 2470-2480.
7. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, et al. (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362: 789-797. (Pubitemid 37093920)
8. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, et al. (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374: 29-38.
9. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, et al. (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32: 2781-2789.
10. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, et al. (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366: 9-19.
11. Lev EI, Hasdai D, Scapa E, Tobar A, Assali A, et al. (2004) Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. J Am Coll Cardiol 43: 966-971. (Pubitemid 38352973)
12. Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, et al. (2011) A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost 9: 2029-2037.
13. Swartz MJ, Mitchell HL, Cox DJ, Reeck GR (1977) Isolation and characterization of trypsin inhibitor from opaque-2 corn seeds. J Biol Chem 252: 8105-8107. (Pubitemid 8243697)
14. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL (1996) Platelets and shear stress. Blood 88: 1525-1541. (Pubitemid 26307046)
15. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, et al. (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33: 4-15. (Pubitemid 37449290)
16. Furugohri T, Sugiyama N, Morishima Y, Shibano T (2011) Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 106: 1076-1083.
17. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, et al. (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108: 217-224.
18. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, et al. (2010) Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 30: 376-381.
19. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103: 879-887. (Pubitemid 29152634)
20. Kimmelstiel C, Zhang P, Kapur NK, Weintraub A, Krishnamurthy B, et al. (2011) Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 4: 171-179.
21. Nylander S, Mattsson C, Ramstrom S, Lindahl TL (2004) Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol 142: 1325-1331. (Pubitemid 39178886)
22. Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP (2006) P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 4: 638-647.
23. Monroe DM, Hoffman M (2006) What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26: 41-48. (Pubitemid 43732226)
24. Fogelson AL, Tania N (2005) Coagulation under flow: the influence of flow-mediated transport on the initiation and inhibition of coagulation. Pathophysiol Haemost Thromb 34: 91-108.
25. Luan D, Zai M, Varner JD (2007) Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol 3: e142.
26. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
27. Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulants. Blood 115: 15-20.
28. Andre P, LaRocca T, Delaney SM, Lin PH, Vincent D, et al. (2003) Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 108: 2697-2703. (Pubitemid 37466813)